Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson?s and Alzheimer?s Disease

Posted Jun 13 2010 5:00pm

Description of Invention:
Activated microglia mediate inflammation in the CNS by secreting various cytokines and free radicals that could damage neurons. Brains from patients with Parkinson disease show microglia reaction, and previous studies by this laboratory show microglia activation leads to inflammation mediated dopaminergic degeneration. Thus identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in Parkinson’s Disease, Alzheimer’s Disease, ischemia and other degenerative CNS disorders.

Considerable research has shown the ability of various peptides to attenuate microglia activation and prevent neuronal degeneration in vitro with a bi-modal dose response curve. These peptides demonstrate maximum effects at femto-molar and micro-molar concentrations. These inventors have now discovered small-peptide and non-peptide molecules that also inhibit microglia and prevent neuronal degeneration with the same bi-modal dose response curve. The non-peptide compounds have also been shown to prevent dopamine neuronal degeneration in animal models. The present invention provides compositions and methods for inhibiting inflammatory mechanisms and treating inflammation-related condition by administering ultra-low (femto-molar) doses of at least one compound of the invention. These compounds include morphinans, opioid peptides, and the tripeptide GGF.

Inventors:
Jau-Shyong Hong (NIEHS)


Patent Status:
HHS, Reference No. E-130-2004/0
US, Application No. 11/596,296 filed 13 Nov 2006


Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research with the inventors via a Cooperative Research and Development Agreement (CRADA).


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Central Nervous System
Central Nervous System - Therapeutics
In-vitro Data



For Additional Information Please Contact:
Norbert Pontzer Ph.D., J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 23,
Rockville, MD 20852
United States
Email: pontzern@mail.nih.gov
Phone: 301-435-5502
Fax: 301-402-0220


Ref No: 1010

Updated: 06/2010

Post a comment
Write a comment:

Related Searches